#Japan #Tokyo #Global Development #Richmond Pharmacology #UK as Gateway

International Seminar: UK as a Gateway to Global Development

Richmond Pharmacology, in collaboration with the British Embassy in Japan, will host an international seminar titled UK as a Gateway to Global Development on October 14, 2026. This event will take place at the British Ambassador’s Residence in Tokyo and aims to explore the pivotal role of the UK in global clinical development, particularly for Japanese pharmaceutical and biotech companies.

Located in the heart of London, Richmond Pharmacology is renowned for offering a comprehensive range of services as a Contract Research Organization (CRO). With expertise in clinical trials and regulatory strategies, Richmond has distinguished itself by leading the world in recruiting participants for in-vivo gene editing trials. Moreover, its adaptive design capabilities enable the execution of trials across various ethnic groups for cutting-edge modalities such as RNAi therapeutics and monoclonal antibodies.

Event Focus

The seminar will focus on strategies for leveraging the UK as a central hub in the global clinical development landscape. It will delve into two main development streams:
1. Japan to Global: This segment will cater to Japanese companies aiming to expand internationally, highlighting the various early clinical development opportunities available in the UK. Topics such as First-in-Human (FIH) studies, patient access, and the support from AMED for overseas clinical development will be discussed.
2. Global to Japan: This segment will address global companies looking to establish their presence in Japan. Following the changes in PMDA policy announced in December 2023, discussions will center around practical challenges in initiating late-phase clinical trials in Japan, advantages of Japanese data in overseas early trials, and risk reduction strategies through informed trial design.

Envisioning Japan's entry into global markets from an early stage of overseas development can significantly lower uncertainties faced during domestic trials, enabling more informed decision-making and better trial designs.

Expert Participation

Attendees can look forward to insightful presentations from leading experts in the field of clinical development, regulations, and the pharmaceutical and biotech industries from both the UK and Japan. A panel discussion will further deepen the dialogue on relevant topics, allowing participants to engage directly with presenters.

Following the seminar, a Networking Reception will provide opportunities for attendees to mingle with speakers and other participants, fostering collaborations and knowledge exchange.

Registration Details

To attend this exciting event, please register by October 2, 2026, at 18:00 via the Peatix page:
Registration Link.

Event Overview

• - Date: October 14, 2026
• - Time: Registration at 14:00, Seminar from 14:30-17:35, Networking Reception from 17:35-18:30
• - Venue: British Ambassador’s Residence, Chiyoda-ku, Tokyo
• - Format: In-person only
• - Cost: Free
• - Capacity: Approximately 100 participants
• - Co-organizers: British Embassy in Japan, Richmond Pharmacology Limited

Target Audience

This seminar is particularly designed for professionals involved in drug discovery and clinical development across various sectors, including:

• - Pharmaceutical and Biotech Companies
• - Venture Capitalists and Investors
• - Academics and Research Institutions
• - Regulatory Authorities and Government Agencies
• - Healthcare Institutions and Clinical Research Entities

Please note that prior approval is required for attendance. Simply registering through Peatix does not guarantee participation. We will review your application and send a confirmation of attendance accordingly.

Program Schedule

• - 14:00-14:30: Registration and Networking
• - 14:30-14:40: Opening Remarks
• - 14:40-15:00: Risk Management via a Consistent Clinical Development Framework
• - 15:00-15:20: Reasons Why Major US Biotech Firms Choose the UK as a Global Development Base
• - 15:20-15:40: Accelerating Global Clinical Development by Japanese Biotech Through AMED Support
• - 15:40-16:00: Challenges of Initiating Late-Phase Clinical Trials in Japan After PMDA Policy Changes
• - 16:00-16:20: Gathering Japanese Data in Overseas Trials with an Eye on Domestic Development – Practical Models of Japan-UK Collaboration
• - 16:20-16:45: Coffee Break and Networking
• - 16:45-17:30: Panel Discussion on Clinical Trial Design Considerations for Global Development and Entry into Japan
• - 17:30-17:35: Closing Remarks
• - 17:35-18:30: Networking Reception

Please note that the program and speakers may be subject to change without notice.

Featured Speakers

• - Dr. Jörg Täubel, Richmond Pharmacology
• - Dr. Lisa Campbell, Richmond Pharmacology
• - Yoshiaki Maruyama, PMDA
• - Andrew Thomson, Former EMA/MHRA
• - Minori Miyahata, A2 Healthcare
• - Additional experts in UK and EU regulatory affairs

Join us for an engaging seminar that aims to enhance global collaboration and innovation in the clinical development space!